Trispecific T-cell engagers target two tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.
Jeffrey V. Matous, MD, discusses moving fixed-duration T-cell–redirecting therapy into frontline multiple myeloma treatment ...
C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.
The FDA has approved the kinase inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally ...
The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...
FDA labeling now reports a 49.7-month median DOR in TKI-naive advanced ROS1+ NSCLC from TRUST-I, based on 51-month median ...
Zidesamtinib (Jideytro) demonstrated a high objective response rate (ORR) in patients with previously untreated ROS1-positive ...
The FDA has approved aminolevulinic acid (ALA) hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic ...
FDA recommended a new survival-confirmatory trial prior to BLA submission, despite statistically significant ORR and PFS ...
The FDA has approved Pixclara (floretyrosine F 18), the first FET-PET imaging agent for distinguishing recurrent glioma from treatment-related change. The FDA has approved floretyrosine F 18 (18F-FET; ...
Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that ...
David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results